RESUMEN
Selection of the ideal antiseptic or antimicrobial treatment for contaminated wounds remains a controversial decision. Clinical decisions are often made on the basis of in vitro studies and personal preference. Although topical solutions are widely used, their comparative in vivo effects on wound healing are largely unreported.A porcine wound model was used to compare five commonly used topical agents-5% mafenide acetate (Sulfamylon solution), 10% povidone with 1% free iodine (Betadine), 0.25% sodium hypochlorite ("half-strength" Dakin), 3% hydrogen peroxide, and 0.25% acetic acid-with a control group. Reepithelialization, angiogenesis, neodermal regeneration, fibroblast proliferation, collagen production, and bacterial colony counts were analyzed at 4 and 7 days after wounding (n = 4). Reepithelialization was not significantly influenced among the various treatment modalities tested. Sulfamylon and Dakin solutions significantly increased neodermal thickness (p < 0.05), whereas hydrogen peroxide and acetic acid significantly inhibited neodermal formation (p < 0.001). All treatments except hydrogen peroxide significantly increased fibroblast proliferation. Sulfamylon and Betadine significantly enhanced angiogenesis (p < 0.05). Sulfamylon proved most effective in maintaining an aseptic environment while concomitantly increasing angiogenesis, fibroblast proliferation, and dermal thickness compared with control. These data show that selection of a particular topical treatment can affect various aspects of wound repair in an animal model. These results suggest that the selection of topical treatments in the clinical setting should be carefully tailored to match unique wound situations and therapeutic endpoints.
Asunto(s)
Peróxido de Hidrógeno/farmacología , Mafenida/farmacología , Povidona/farmacología , Hipoclorito de Sodio/farmacología , Cicatrización de Heridas/efectos de los fármacos , Administración Tópica , Animales , Peróxido de Hidrógeno/administración & dosificación , Mafenida/administración & dosificación , Povidona/administración & dosificación , Hipoclorito de Sodio/administración & dosificación , PorcinosRESUMEN
Two methods of determining diet botanical composition, microhistological (MH), and stable carbon isotope ratio (CR) analyses were used to determine botanical composition of ingesta and fecal grab samples in steers grazing rhizoma peanut-mixed tropical grass pastures. Three pastures were used over two grazing seasons, 1992 and 1993, in Brooksville, FL. A weighted-disc double-sampling technique was used to determine forage mass and botanical composition, percentage of rhizoma peanut (Arachis glabrata), grass (Paspalum notatum and Cynodon dactlyon), and forb (primarily Chenopodium ambrosioides) on offer every 28 d throughout the grazing seasons. There was an effect of sampling date (P<.001), sampling date x pasture (P<.001), and sampling date x year (P<.001) on forage mass on offer. There was a pasture x year x sampling date interaction (P<.001) for all botanical components. In 1992 and 1993, using cannulated steers sampled every 56 d, there were interactions with year for rhizoma peanut and forb (P<.05), but not for grass with MH analysis (components: rhizoma peanut, grass, and forb). Ingesta and fecal rhizoma peanut (r = .73 and .92 for 1992 and 1993, respectively) and ingesta and fecal forb (r = .86 and .98 for 1992 and 1993, respectively) were positively correlated (P<.001). Ingesta and fecal grass were positively correlated (r = .52, P<.001), but the correlation was not as high. With the CR analysis (components: Calvin cycle [C3] plants and C4-dicarboxylic acid pathway [C4] plants), ingesta and corrected fecal (corrected for in vitro organic matter digestibility [IVOMD]) C3 plants were positively correlated (r = .62; P<.001). Diet composition of fecal grab samples from noncannulated steers, collected on the same sampling schedule as for hand-clipped pasture samples, differed at times due to the complexity of the sward (both rhizoma peanut and forb constituted a single component, C3, in the CR analysis). Based on these results, if there is a substantial contribution of forb to the diet, fecal microhistological analysis may be more informative than fecal carbon ratio analysis for estimating diet selection by cattle grazing tropical pastures.
Asunto(s)
Fenómenos Fisiológicos Nutricionales de los Animales , Bovinos/fisiología , Dieta , Estaciones del Año , Animales , Isótopos de Carbono , Heces/química , Conducta Alimentaria , Masculino , PoaceaeRESUMEN
During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery of E. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.
Asunto(s)
Escherichia coli/enzimología , Terapia Genética , Neoplasias/terapia , Profármacos/farmacocinética , Purina-Nucleósido Fosforilasa/metabolismo , Animales , Biotransformación , Flucitosina/farmacocinética , Ganciclovir/farmacocinética , Ratones , Ratones Desnudos , Purina-Nucleósido Fosforilasa/genética , Simplexvirus/enzimología , Timidina Quinasa/genéticaRESUMEN
In an effort to understand biochemical features that are important to the selective antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine [Cl-F( upward arrow)-dAdo], we evaluated the biochemical pharmacology of three structurally similar compounds that have quite different antitumor activities. Cl-F( upward arrow)-dAdo was 50-fold more potent as an inhibitor of CEM cell growth than were either 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine [Cl-F( downward arrow)-dAdo] or 2-chloro-9-(2-deoxy-2, 2-difluoro-beta-D-ribofuranosyl)adenine [Cl-diF( upward arrow downward arrow)-dAdo]. The compounds were similar as substrates of deoxycytidine kinase. Similar amounts of their respective triphosphates accumulated in CEM cells, and the rate of disappearance of these metabolites was also similar. Cl-F( upward arrow)-dAdo was 10- to 30-fold more potent in its ability to inhibit the incorporation of cytidine into deoxycytidine nucleotides than either Cl-F( downward arrow)-dAdo or Cl-diF( upward arrow downward arrow)-dAdo, respectively, which indicated that ribonucleotide reductase was differentially inhibited by these three compounds. Thus, the differences in the cytotoxicity of these agents toward CEM cells were not related to quantitative differences in the phosphorylation of these agents to active forms but can mostly be accounted for by differences in the inhibition of ribonucleotide reductase activity. Furthermore, the inhibition of RNA and protein synthesis by Cl-F( downward arrow)-dAdo and Cl-diF( upward arrow downward arrow)-dAdo at concentrations similar to those required for the inhibition of DNA synthesis can help explain the poor antitumor selectivity of these two agents because all cells require RNA and protein synthesis.
Asunto(s)
Antineoplásicos/farmacología , Arabinonucleósidos/farmacología , Desoxiadenosinas/farmacología , Nucleótidos de Adenina , División Celular/efectos de los fármacos , Clofarabina , ADN/biosíntesis , ADN/efectos de los fármacos , Desoxicitidina/metabolismo , Desoxicitidina Quinasa/antagonistas & inhibidores , Desoxicitidina Quinasa/aislamiento & purificación , Desoxicitidina Quinasa/metabolismo , Inhibidores Enzimáticos/farmacología , Humanos , Sustancias Macromoleculares , Fosforilación/efectos de los fármacos , Especificidad por Sustrato , Tritio , Células Tumorales CultivadasRESUMEN
Activation of purine nucleoside analogs by Escherichia coli purine nucleoside phosphorylase (PNP) is being evaluated as a suicide gene therapy strategy for the treatment of cancer. Because the mechanisms of action of two toxic purine bases, 6-methylpurine (MeP) and 2-fluoroadenine (F-Ade), that are generated by this approach are poorly understood, mechanistic studies were initiated to learn how these compounds differ from agents that are being used currently. The concentration of F-Ade, MeP, or 5-fluorouracil required to inhibit CEM cell growth by 50% after a 4-hr incubation was 0.15, 9, or 120 microM, respectively. F-Ade and MeP were also toxic to quiescent MRC-5, CEM, and Balb 3T3 cells. Treatment of CEM, MRC-5, or Balb 3T3 cells with either F-Ade or MeP resulted in the inhibition of protein, RNA, and DNA syntheses. CEM cells converted F-Ade and MeP to F-ATP and MeP-ribonucleoside triphosphate (MeP-R-TP), respectively. The half-life for disappearance of HeP-ribonucleoside triphosphate from CEM cells was approximately 48 hr, whereas the half-lives of F-ATP and ATP were approximately 5 hr. Both MeP and F-Ade were incorporated into the RNA and DNA of CEM cells. These studies indicated that the mechanisms of action of F-Ade and MeP were quite different from those of other anticancer agents, and suggested that the generation of these agents in tumor cells by E. coli PNP could result in significant advantages over those generated by either herpes simplex virus thymidine kinase or E. coli cytosine deaminase. These advantages include a novel mechanism of action resulting in toxicity to nonproliferating and proliferating tumor cells and the high potency of these agents during short-term treatment.
Asunto(s)
Adenina/análogos & derivados , Purinas/metabolismo , Células 3T3 , Adenina/metabolismo , Animales , División Celular/efectos de los fármacos , Línea Celular , Cicloheximida/farmacología , ADN/efectos de los fármacos , ADN/metabolismo , Fluorouracilo/farmacología , Humanos , Ratones , Inhibidores de la Síntesis del Ácido Nucleico/farmacología , Inhibidores de la Síntesis de la Proteína/farmacología , ARN/efectos de los fármacos , ARN/metabolismoRESUMEN
The carbocyclic analog of 2'-deoxyguanosine (CdG) has broad-spectrum antiviral activity. Because of recent observations with other nucleoside analogs that biological activity may be associated the L enantiomer rather than, as expected, with the D enantiomer, we have studied the metabolism of both enantiomers of CdG to identify the enzymes responsible for the phosphorylation of CdG in noninfected and virally infected human and duck cells. We have examined the enantiomers as substrates for each of the cellular enzymes known to catalyze phosphorylation of deoxyguanosine. Both enantiomers of CdG were substrates for deoxycytidine kinase (EC 2.7.1.74) from MOLT-4 cells, 5'-nucleotidase (EC 3.1.3.5) from HEp-2 cells, and mitochondrial deoxyguanosine kinase (EC 2.7.1.113) from human platelets and CEM cells. For both deoxycytidine kinase and mitochondrial deoxyguanosine kinase, the L enantiomer was the better substrate. Even though the D enantiomer was the preferred substrate with 5'-nucleotidase, the rate of phosphorylation of the L enantiomer was substantial. The phosphorylation of D-CdG in MRC-5 cells was greatly stimulated by infection with human cytomegalovirus. The fact that the phosphorylation of D-CdG was stimulated by mycophenolic acid and was not affected by deoxycytidine suggested that 5'-nucleotidase was the enzyme primarily responsible for its metabolism in virally infected cells. D-CdG was extensively phosphorylated in duck hepatocytes, and its phosphorylation was not affected by infection with duck hepatitis B virus. These results are of importance in understanding the mode of action of D-CdG and related analogs and in the design of new biologically active analogs.
Asunto(s)
5'-Nucleotidasa/metabolismo , Desoxicitidina Quinasa/metabolismo , Desoxiguanosina/análogos & derivados , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Animales , Antibióticos Antineoplásicos/farmacología , Células Cultivadas/enzimología , Células Cultivadas/virología , Citomegalovirus/efectos de los fármacos , Desoxiguanosina/química , Desoxiguanosina/metabolismo , Desoxiguanosina/farmacología , Patos , Humanos , Mitocondrias/efectos de los fármacos , Mitocondrias/enzimología , Ácido Micofenólico/farmacología , Nucleósidos/farmacología , Fosforilación/efectos de los fármacos , Estereoisomerismo , Especificidad por SustratoRESUMEN
We have developed a new strategy for the gene therapy of cancer based on the activation of purine nucleoside analogs by transduced E. coli purine nucleoside phosphorylase (PNP, E.C. 2.4.2.1). The approach is designed to generate antimetabolites intracellularly that would be too toxic for systemic administration. To determine whether this strategy could be used to kill tumor cells without host toxicity, nude mice bearing human malignant D54MG glioma tumors expressing E. coli PNP (D54-PNP) were treated with either 6-methylpurine-2'-deoxyriboside (MeP-dR) or arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP, fludarabine, a precursor of F-araA). Both prodrugs exhibited significant antitumor activity against established D54-PNP tumors at doses that produced no discernible systemic toxicity. Significantly, MeP-dR was curative against this slow growing solid tumor after only 3 doses. The antitumor effects showed a dose dependence on both the amount of prodrug given and the level of E. coli PNP expression within tumor xenografts. These results indicated that a strategy using E. coli PNP to create highly toxic, membrane permeant compounds that kill both replicating and nonreplicating cells is feasible in vivo, further supporting development of this cancer gene therapy approach.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Terapia Genética/métodos , Glioma/tratamiento farmacológico , Profármacos/farmacología , Purina-Nucleósido Fosforilasa/fisiología , Animales , Antimetabolitos Antineoplásicos/toxicidad , Escherichia coli/enzimología , Escherichia coli/genética , Vectores Genéticos/genética , Humanos , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Nucleósidos de Purina/uso terapéutico , Nucleósidos de Purina/toxicidad , Purina-Nucleósido Fosforilasa/genética , Retroviridae/genética , Fosfato de Vidarabina/análogos & derivados , Fosfato de Vidarabina/uso terapéutico , Fosfato de Vidarabina/toxicidadRESUMEN
Carbovir (CBV) is a guanine nucleoside analog with potent in vitro anti-HIV activity. A prodrug of CBV is currently being evaluated in clinical trials as a potential agent for the treatment of AIDS. The ability of CBV to inhibit mitochondrial DNA synthesis in intact CEM cells was evaluated in the present study, because most of the currently available anti-HIV nucleoside analogs have significant toxicities that result from their inhibition of mitochondrial DNA synthesis. No delayed cytotoxicity was observed in CEM cells treated with 50 microM CBV for 4 weeks. In addition, CBV at concentrations as high as 1 mM did not cause a decline in mitochondrial DNA levels and only minimally increased the concentration of lactic acid in the medium. In contrast to these results with CBV, treatment of CEM cells with 0.5 microM 2',3'-dideoxycytidine resulted in delayed cytotoxicity, a decrease in mitochondrial DNA content and increases in lactic acid levels in the medium. These results indicated that treatment of CEM cells with CBV did not result in the inhibition of mitochondrial DNA synthesis and suggested that treatment of AIDS patients with CBV, or a prodrug of CBV, would not result in some of the toxicities seen with the other anti-HIV nucleoside analogs.
Asunto(s)
Fármacos Anti-VIH/toxicidad , Didesoxinucleósidos/toxicidad , Mitocondrias/efectos de los fármacos , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/virología , Línea Celular , ADN Mitocondrial/biosíntesis , Evaluación Preclínica de Medicamentos , Humanos , Ácido Láctico/metabolismo , Mitocondrias/metabolismo , Profármacos/toxicidad , Zalcitabina/toxicidadRESUMEN
4'-Thiothymidine (S-dThd) is a potent inhibitor of L1210 cell growth and is active against P388 leukemia in mice. Because of these activities and its novel structure, we have begun studies of its metabolism and metabolic actions in L1210 cells in order to understand its mechanism of cytotoxicity, S-dThd inhibited the incorporation of radiolabeled precursors into DNA, but did not inhibit the incorporation of either uridine or leucine into RNA or protein, respectively, which indicated that the mechanism of its toxicity was due to its inhibition of DNA synthesis. S-dThd did not decrease the concentration of any of the natural deoxynucleoside triphosphates, which indicated that its cytotoxicity was not due to the inhibition of ribonucleotide reductase. S-dThd was readily phosphorylated and used as a substrate for DNA synthesis. Because the rate of incorporation of S-dThd into DNA was 20% that of thymidine, it is likely that the mechanism of action of S-dThd is not due to inhibition of DNA polymerases by the 5'-triphosphate of S-dThd, but instead to its incorporation into the DNA and its subsequent disruption of some function of DNA.
Asunto(s)
Antineoplásicos/farmacología , Tionucleósidos/farmacología , Timidina/análogos & derivados , Animales , Antineoplásicos/metabolismo , División Celular/efectos de los fármacos , Replicación del ADN/efectos de los fármacos , ADN de Neoplasias/biosíntesis , ADN de Neoplasias/metabolismo , Leucemia L1210 , Ratones , Especificidad por Sustrato , Tionucleósidos/metabolismo , Timidina/metabolismo , Timidina/farmacología , Timidina Quinasa/metabolismo , Células Tumorales CultivadasRESUMEN
Steers (n = 156) finished on rhizoma peanut (Arachis glabrata Benth.)-tropical grass pasture in Florida and slaughtered at Central Packing, Center Hill were compared with steers (n = 152) finished on a concentrate diet in Texas and slaughtered at Excel, Plainview. Average daily gain during the growing and finishing periods was lower (P < .001) for forage-finished steers (.49 and .94 kg/d, respectively) than for concentrate-finished steers (.78 and 1.33 kg/d, respectively). Forage-finished steers had less fat over the ribeye (8.3 vs 11.4 mm; P < .01), lighter hot carcass weight (280 vs 346 kg; P < .001), and smaller longissimus muscle area (70.8 vs 86.6 cm2; P < .001) than concentrate-finished steers. Yield grade was not different (2.7 vs 2.6; P > .10), but quality grade was slightly better (low Select vs mid Select; P < .01) for concentrate-finished steers. Lean color of forage-finished steers was darker (P < .001) and fat of forage-finished steers had a creamier color (P < .001), but carcasses were not discounted due to yellow fat color. Shear force values were higher (6.8 vs 4.0 kg; P < .001) for forage-finished than for concentrate-finished steers. Off-flavors were detected by trained sensory panelists in 36% of forage-finished and 14% of concentrate-finished carcasses, but all at barely detectable levels. This research indicates that steers can be finished on rhizoma peanut-tropical grass pastures, but with some reduction in quality grade relative to concentrate-finished steers.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Alimentación Animal/normas , Composición Corporal/fisiología , Peso Corporal/fisiología , Bovinos/crecimiento & desarrollo , Carne/normas , Animales , Arachis/normas , Cruzamiento , Florida , Masculino , Músculo Esquelético/fisiología , Poaceae , TexasRESUMEN
Inefficiency of gene delivery, together with inadequate bystander killing, represent two major hurdles in the development of a toxin-mediated gene therapy for human malignancy. The product of the Escherischia coli DeoD gene (purine nucleoside phosphorylase, PNP) differs from the mammalian enzyme in its substrate specificity and is capable of catalyzing the conversion of several non-toxic deoxyadenosine analogs to highly toxic adenine analogs. We have found that expression of E. coli PNP in < 1% of a human colonic carcinoma cell line leads to the death of virtually all bystander cells after treatment with 6-methyl-purine-2'-deoxyribonucleoside, a deoxyadenosine analog that is a substrate for E. coli PNP but not human PNP. Minimal toxicity was observed in non-transfected or E. coli LacZ transfected cells that were treated with this compound. These results establish a rational approach to achieve significant bystander killing, even after gene transfer to only a small fraction of tumor cells.
Asunto(s)
Neoplasias del Colon/terapia , Escherichia coli/genética , Terapia Genética , Secuencia de Bases , Muerte Celular/efectos de los fármacos , Neoplasias del Colon/genética , Neoplasias del Colon/metabolismo , Cartilla de ADN/genética , Técnicas de Transferencia de Gen , Genes Bacterianos , Humanos , Operón Lac , Datos de Secuencia Molecular , Purina-Nucleósido Fosforilasa/genética , Purina-Nucleósido Fosforilasa/metabolismo , Purinas/biosíntesis , Purinas/toxicidad , Transfección , Células Tumorales CultivadasRESUMEN
6-Thio-2'-deoxyguanosine (T-dGuo) has been reported to be both phosphorylated by deoxycytidine kinase and converted to 6-thioguanine by purine nucleoside phosphorylase (PNP). Combination of T-dGuo with an inhibitor of PNP would be expected to generate the 5'-triphosphate of T-dGuo and limit or prevent the formation of 6-thioguanosine triphosphate. Because the incorporation of 6-thioguanine into DNA is believed to be primarily responsible for the antitumor activity of the thiopurines, this treatment might result in enhanced activity against certain tumors, particularly those of T-cell origin. We have evaluated the metabolic basis of this strategy by examining the effects of 9-benzyl-9-deazaguanine (BDG), a potent inhibitor of PNP, on the metabolism of T-dGuo in CEM cells. The concentration of T-dGuo required to inhibit cell growth by 50% was approximately 50-fold greater in the presence of 8.0 microM BDG than in its absence. As expected, the addition of BDG to cells treated with T-dGuo prevented the metabolism of T-dGuo to 6-thio-guanine-containing ribo-nucleotides, but, unexpectedly, no 6-thio-2'-deoxyguanosine 5'-triphosphate was detected. In cells treated with T-dGuo plus BDG, the major phosphorylated metabolite was T-dGMP. These results indicated that even in the absence of PNP activity, T-dGuo cannot be phosphorylated directly to 6-thio-2'-deoxyguanosine 5'-triphosphate due to the inability of guanylate kinase to utilize T-dGMP as a substrate.
Asunto(s)
Compuestos de Bencilo/farmacología , Desoxiguanosina/análogos & derivados , Guanina/análogos & derivados , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Tionucleósidos/toxicidad , Biotransformación , División Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Desoxiguanosina/metabolismo , Desoxiguanosina/toxicidad , Relación Dosis-Respuesta a Droga , Guanina/farmacología , Humanos , Tionucleósidos/metabolismoRESUMEN
Cyclopentadiene was converted in six steps to the key intermediate (+/-)-(1 alpha,2 beta,4 alpha)-4-amino-2-(benzyloxy)cyclopentanol (10), which in turn was converted to the carbocyclic nucleoside analogs 14 and 19 by standard procedures developed in these laboratories. Compounds 14 and 19 were then further converted to the target phosphonates 1b and 2b by modification of literature procedures. The phosphonate 1b was 40-fold more cytotoxic to HEp-2 cells than its parent, CDG, presumably after conversion to the diphosphoryl phosphonate.
Asunto(s)
Antineoplásicos/síntesis química , Nucleótidos Cíclicos/síntesis química , Organofosfonatos/síntesis química , Animales , Antineoplásicos/farmacología , Carcinoma de Células Escamosas/tratamiento farmacológico , Humanos , Leucemia L1210/tratamiento farmacológico , Ratones , Nucleótidos Cíclicos/farmacología , Organofosfonatos/farmacología , Porcinos , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
CdG, the carbocyclic analog of 2'-deoxyguanosine, is active against herpes, hepatitis B, and human cytomegaloviruses. We have studied the interaction of the tritiated enantiomers of CdG with the herpes simplex virus type 1-specific thymidine kinase (HSV-1 TK) and have examined their metabolism in uninfected and HSV-1-infected cells. D- and L-CdG were equally effective competitive inhibitors of the phosphorylation of thymidine (dThd) by the partially purified HSV-1 TK (Ki values were 2.1 and 3.4 microM, respectively) and were also equal as substrates (Km values were 17 and 26 microM, respectively, and Vmax values of the enantiomers were equal and about 50% greater than the Vmax for dThd). The partially purified enzyme preparation, which contained cellular nucleotide kinase activities (pyruvate kinase also was present in the assay medium), converted D-CdG almost exclusively to the triphosphate and L-CdG almost exclusively to the monophosphate. Similarly, in virus-infected cells the D-enantiomer was converted predominantly to the triphosphate and the L-enantiomer predominantly to the monophosphate. In uninfected cells the results were qualitatively similar. In CEM cells deoxycytidine (dCyd) kinase (EC 2.7.1.74) seemed to be the enzyme principally responsible for the phosphorylation of both enantiomers, as shown by competition studies. Thus, both the HSV-1 TK and cellular dCyd kinase (of CEM cells) showed no selectivity for the enantiomers of CdG. This lack of enantiomeric specificity has obvious implications for the design of inhibitors of both viral proliferation and cellular metabolism.
Asunto(s)
Antivirales/metabolismo , Desoxiguanosina/análogos & derivados , Simplexvirus/enzimología , Timidina Quinasa/metabolismo , Desoxiguanosina/química , Desoxiguanosina/metabolismo , Guanilato-Quinasas , Células HeLa , Humanos , Nucleósido-Fosfato Quinasa/metabolismo , Fosforilación , Estereoisomerismo , Especificidad por SustratoRESUMEN
Certain derivatives of 9-deazaguanine that contain arylmethyl, heteroarylmethyl or cycloalkylmethyl groups at the 9-position are potent inhibitors of purine nucleoside phosphorylase (PNP, E.C. 2.4.2.1). To determine whether these agents can produce metabolically significant inhibition of PNP in cells and in animals, the authors performed pharmacological studies with a representative member of the series, 9-benzyl-9-deazaguanine (BzDAG). BzDAG was a potent inhibitor of PNP from calf spleen (Ki = 12 nM). It was also an effective inhibitor of PNP in cells and in animals as shown by the findings that it 1) inhibited the conversion of inosine to nucleotides in L1210 cells in culture at concentrations that had little effect on the utilization of hypoxanthine; 2) potentiated the toxicity of deoxyguanosine to CCRF-CEM cells in culture; 3) increased the pools of deoxy GTP in CCRF-CEM, Molt-3 and Molt-4 cells that had been treated with deoxyguanosine; 4) prevented the toxicity of 6-thioguanosine to HEp-2 cells in culture; 5) increased the plasma levels of endogenous inosine in rats; and 6) increased the plasma levels of 2',3'-dideoxyinosine in rats that had received BzDAG and dideoxyinosine in combination. Pharmacokinetic analysis of BzDAG in the rat showed it to be 48% orally bioavailable (at a dose of 5 mg/kg). About 95% of BzDAG was protein bound. After i.v. administration of BzDAG (5 mg/kg), more than 50% of the erythrocyte PNP was inhibited for 40 min. These results indicate that the 9-substituted-9-deazaguanines are potent orally active PNP inhibitors and are therefore of potential clinical interest as immunosuppressive and anti-inflammatory agents.
Asunto(s)
Compuestos de Bencilo/farmacología , Guanina/análogos & derivados , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Animales , Compuestos de Bencilo/metabolismo , Proteínas Sanguíneas/metabolismo , Desoxiguanosina/metabolismo , Desoxiguanosina/farmacología , Eritrocitos/enzimología , Guanina/metabolismo , Guanina/farmacología , Guanosina/análogos & derivados , Guanosina/farmacología , Inosina/metabolismo , Leucemia L1210/metabolismo , Masculino , Unión Proteica , Ratas , Ratas Endogámicas Lew , Tionucleósidos/farmacologíaRESUMEN
Carbovir (CBV) [the (--)-enantiomer of the carbocyclic analog of 2',3'-dideoxy-2',3'-didehydroguanosine] is a potent inhibitor of human immunodeficiency virus type 1 (HIV) replication in vitro. We have characterized the metabolism of CBV and its effect on cellular metabolism in an effort to better understand its mechanism of action. CBV was primarily metabolized to the 5'-triphosphate of CBV (CBV-TP) to concentrations sufficient to inhibit HIV reverse transcriptase. Infection of CEM cells with HIV did not affect the metabolism of CBV. In CEM cells, there was no evidence of the degradation of CBV by purine nucleoside phosphorylase. The half-life of CBV-TP in CEM cells was 2.5 h, similar to that of the 5'-triphosphate of zidovudine (AZT). However, unlike the levels of the 5'-triphosphate of AZT, CBV-TP levels declined without evidence of a plateau. CBV did not affect the metabolism of AZT, and AZT did not affect the metabolism of CBV. A small amount of CBV was incorporated into DNA in intact CEM cells, and this incorporation was increased by incubation with mycophenolic acid, an inhibitor of IMP dehydrogenase. CBV specifically inhibited the incorporation of nucleic acid precursors into DNA but had no effect on the incorporation of radiolabeled precursors into RNA or protein. CBV did not decrease the level of TTP, dGTP, dCTP, or dATP. These results suggested that the cytotoxicity of CBV was due to the inhibition of DNA synthesis. Further studies are necessary to identify the target(s) responsible for growth inhibition.
Asunto(s)
Antivirales/metabolismo , Antivirales/farmacología , Didesoxinucleósidos/metabolismo , Didesoxinucleósidos/farmacología , VIH-1/efectos de los fármacos , Línea Celular , ADN/metabolismo , Sinergismo Farmacológico , VIH-1/metabolismo , Semivida , Humanos , Ácido Micofenólico/farmacología , ARN/metabolismo , Zidovudina/farmacologíaRESUMEN
The carbocyclic analog of 2'-deoxyguanosine (CdG) is active against herpes simplex virus (HSV), human cytomegalovirus, and human hepatitis-B virus. In order to understand the mechanism of action of this compound against HSV, we have evaluated (a) the incorporation of [3H]CdG into viral and host DNA in HEp-2 cells infected with HSV and (b) the interaction of the 5'-triphosphate of CdG (CdG-TP) with the HSV DNA polymerase and human DNA polymerases alpha, beta, and gamma (EC 2.7.7.7). Incubation of HSV-1-infected HEp-2 cells with [3H]CdG resulted in the incorporation of CdG into both the HSV and the host cell DNA. These results indicated that CdG-TP was used as a substrate for HSV DNA polymerase and for at least one of the cellular DNA polymerases. Degradation of both viral and host DNA with micrococcal nuclease and spleen phosphodiesterase indicated that CdG was incorporated primarily into internal positions in both DNAs. The viral DNA containing CdG sedimented in neutral and alkaline sucrose gradients in the same way as did viral DNA labeled with [3H]thymidine, indicating that the HSV DNA containing CdG was similar in size to untreated HSV DNA. CdG-TP was a competitive inhibitor of the incorporation of dGTP into DNA by the HSV DNA polymerase (Ki of 0.35 microM) and the human DNA polymerase alpha (Ki of 1 microM). CdG-TP was not a potent inhibitor of either DNA polymerase beta or gamma. Using DNA-sequencing technology, CdG-TP was found to be an efficient substrate for HSV DNA polymerase. Incorporation of CdG monophosphate (CdG-MP) into the DNA by HSV DNA polymerase did not interfere with subsequent chain extension. These results suggested that the antiviral activity of CdG was due to its incorporation into the DNA and subsequent disruption of viral functions. In contrast, CdG-TP was not as good as dGTP as a substrate for DNA synthesis by DNA polymerase alpha, and incorporation of CdG-MP by DNA polymerase alpha inhibited further DNA chain elongation.
Asunto(s)
ADN Viral/metabolismo , Desoxiguanosina/análogos & derivados , Herpes Simple/metabolismo , Simplexvirus/metabolismo , Secuencia de Bases , ADN Viral/efectos de los fármacos , Nucleótidos de Desoxiguanina/metabolismo , Desoxiguanosina/metabolismo , Humanos , Datos de Secuencia Molecular , Inhibidores de la Síntesis del Ácido Nucleico , Tritio , Proteínas Virales/antagonistas & inhibidoresRESUMEN
Desmosine, the intermolecular and intramolecular cross link between the chains of elastin polypeptide, may be useful as a marker of a lung injury in adult respiratory distress syndrome (ARDS). A radioimmunoassay for rabbit antibody developed against desmosine, conjugated to bovine serum albumin, can detect as little as 100 pg of desmosine in plasma or urine. Desmosine is not metabolically absorbed, reused, or catabolized by the body, but rather eliminated unchanged in the urine as low molecular weight peptides. The lung is relatively rich in elastin, and we reasoned that a timed collection could be used as an index of elastin degradation in vivo. A 2-h collection of urine for desmosine assay was obtained at the time of Swan-Ganz catheter insertion in 41 consecutive patients. On the basis of clinical and initial Swan-Ganz catheter data, the patients were assigned to one of three groups: an ARDS group (n = 12); a cardiogenic pulmonary edema (CPE) group (n = 12); and a critically ill, nonpulmonary edema group (NPE, n = 17). The mean urine desmosine concentration (mg/L) for the ARDS group (0.728 +/- 0.22 SE) differed from the CPE group (0.149 +/- 0.07; p less than 0.001). The total excretion (microgram/2 h) was 64.95 +/- 24.7 in the ARDS group and 24.71 +/- 11.7 in the CPE group (p less than 0.05). Urine desmosine concentration/serum creatinine index for the ARDS group (0.78 +/- 0.28) was greater than in the CPE group (0.07 +/- 0.04; p = 0.019). Desmosine excretion was increased in the NPE group compared with CPE and ARDS groups, possibly reflecting heterogeneity in this group. In the differentiation of ARDS from CPE, we conclude that substantial increases in urinary desmosine excretion favor a diagnosis of ARDS.
Asunto(s)
Desmosina/orina , Enfermedades Pulmonares/orina , Síndrome de Dificultad Respiratoria/complicaciones , Adulto , Gasto Cardíaco , Creatinina/sangre , Creatinina/orina , Humanos , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/fisiopatología , Persona de Mediana Edad , Presión Esfenoidal Pulmonar , Radioinmunoensayo , Síndrome de Dificultad Respiratoria/mortalidad , Síndrome de Dificultad Respiratoria/fisiopatología , Tasa de SupervivenciaRESUMEN
2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-adenine (Cl-F-ara-A) has activity against the P388 tumor in mice on several different schedules. Biochemical studies with a chronic myelogenous leukemia cell line (K562) grown in cell culture have been done in order to better understand its mechanism of action. Cl-F-ara-A was a potent inhibitor of K562 cell growth. Only 5 nM inhibited K562 cell growth by 50% after 72 h of continuous incubation. The 5'-triphosphate of Cl-F-ara-A was detected by strong anion exchange chromatography of the acid-soluble extract of K562 cells incubated with Cl-F-ara-A. Competition studies with natural nucleosides suggested that deoxycytidine kinase was the enzyme responsible for the metabolism to the monophosphate. Incubation of K562 cells for 4 h with 50 nM Cl-F-ara-A inhibited the incorporation of [3H]thymidine into the DNA by 50%. Incubation with 0.1, 1, or 10 microM Cl-F-ara-A for 4 h depressed dATP, dCTP, and dGTP pools but did not affect TTP pools. Similar inhibition of deoxyribonucleoside triphosphate pools was seen after incubation with 2-chloro-2'-deoxyadenosine. Both Cl-F-ara-ATP and Cl-dATP potently inhibited the reduction of ADP to dADP in crude extracts of K562 cells (concentration producing 50% inhibition, 65 nM). The effect of Cl-F-ara-ATP on human DNA polymerases alpha, beta, and gamma isolated from K562 cells grown in culture was determined and compared with those of Cl-dATP and 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate (F-ara-ATP). Cl-F-ara-ATP was a potent inhibitor of DNA polymerase alpha. Inhibition of DNA polymerase alpha was competitive with respect to dATP (Ki of 1 microM). The three analogue triphosphates were incorporated into the DNA by DNA polymerase alpha as efficiently as dATP. The incorporation of Cl-F-ara-AMP inhibited the further elongation of the DNA chain, similarly to that seen after the incorporation of F-ara-AMP. Extension of the DNA chain after the incorporation of Cl-dAMP was not inhibited as much as it was with either Cl-F-ara-AMP or F-ara-AMP. Cl-F-ara-ATP was not a potent inhibitor of DNA polymerase beta, DNA polymerase gamma, or DNA primase.(ABSTRACT TRUNCATED AT 400 WORDS)